Simple blood test could spot three cancers before symptoms appear
NCT ID NCT07236177
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new way to detect cancer by looking at certain enzymes in the blood. Researchers will collect blood samples from 220 people—120 with breast, lung, or pancreatic cancer and 100 without cancer. They want to see if the enzyme levels are different between the groups, which could lead to a simple test for earlier cancer detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 220 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment. Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment. Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment. Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer. Exclusion Criteria: * Refusal to participate in the research. * Patients benefiting from enhanced protection, namely: minors, pregnant/breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection Specific criteria for groups 1, 2, and 3: * Cancer patients undergoing oncological treatment. * Cancer not proven by anatomopathological examination.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
C.H.U. Poitiers
RECRUITINGPoitiers, 86000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a blood test before pancreatic surgery predict a dangerous leak?
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?